This Review Is Part of a Thematic Series on Matrix Metalloproteinases, Which Includes the following Articles: Matrix Metalloproteinase Inhibition after Myocardial Infarction: a New Approach to Prevent Heart Failure? Matrix Metalloproteinases in Vascular Remodeling and Atherogenesis: the Good, the Ba

Abstract— Matrix metalloproteinases (MMPs), also designated matrixins, hydrolyze components of the extracellular matrix. These proteinases play a central role in many biological processes, such as embryogenesis, normal tissue remodeling, wound healing, and angiogenesis, and in diseases such as atheroma, arthritis, cancer, and tissue ulceration. Currently 23 MMP genes have been identified in humans, and most are multidomain proteins. This review describes the members of the matrixin family and discusses substrate specificity, domain structure and function, the activation of proMMPs, the regulation of matrixin activity by tissue inhibitors of metalloproteinases, and their pathophysiological implication.

[1]  J. Eriksson,et al.  Tissue inhibitor of metalloproteinases-3 induces apoptosis in melanoma cells by stabilization of death receptors , 2003, Oncogene.

[2]  Harald Sontheimer,et al.  Chlorotoxin Inhibits Glioma Cell Invasion via Matrix Metalloproteinase-2* , 2003, The Journal of Biological Chemistry.

[3]  B. Strauss,et al.  Matrix remodeling in experimental and human heart failure: a possible regulatory role for TIMP-3. , 2003, American journal of physiology. Heart and circulatory physiology.

[4]  I. Behrmann,et al.  The Matrix Metalloproteinase 9 (MMP-9) Hemopexin Domain Is a Novel Gelatin Binding Domain and Acts as an Antagonist* , 2002, The Journal of Biological Chemistry.

[5]  P. Soloway,et al.  Cellular activation of proMMP‐13 by MT1‐MMP depends on the C‐terminal domain of MMP‐13 , 2002, FEBS letters.

[6]  James B. Graham,et al.  Metalloproteinase-Dependent Predegeneration In Vitro Enhances Axonal Regeneration within Acellular Peripheral Nerve Grafts , 2002, The Journal of Neuroscience.

[7]  Gillian Murphy,et al.  Metalloproteinase inhibitors: biological actions and therapeutic opportunities , 2002, Journal of Cell Science.

[8]  Takanori Aoki,et al.  Matrix Metalloproteinases Cleave Connective Tissue Growth Factor and Reactivate Angiogenic Activity of Vascular Endothelial Growth Factor 165* , 2002, The Journal of Biological Chemistry.

[9]  C. Overall.  Molecular determinants of metalloproteinase substrate specificity , 2002, Molecular biotechnology.

[10]  Jiankun Cui,et al.  S-Nitrosylation of Matrix Metalloproteinases: Signaling Pathway to Neuronal Cell Death , 2002, Science.

[11]  J. Wallace,et al.  Matrix metalloproteinase processing of monocyte chemoattractant proteins generates CC chemokine receptor antagonists with anti-inflammatory properties in vivo. , 2002, Blood.

[12]  Pedro Romero,et al.  Matrix metalloproteinase 9 (MMP-9/gelatinase B) proteolytically cleaves ICAM-1 and participates in tumor cell resistance to natural killer cell-mediated cytotoxicity , 2002, Oncogene.

[13]  R. Huber,et al.  Structural basis of the adaptive molecular recognition by MMP9. , 2002, Journal of molecular biology.

[14]  J. Keski‐Oja,et al.  Epilysin (MMP-28) expression is associated with cell proliferation during epithelial repair. , 2002, The Journal of investigative dermatology.

[15]  Ekaterina Morgunova,et al.  Structural insight into the complex formation of latent matrix metalloproteinase 2 with tissue inhibitor of metalloproteinase 2 , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[16]  A. Newby,et al.  Tissue Inhibitor of Metalloproteinase-3 Induces a Fas-associated Death Domain-dependent Type II Apoptotic Pathway* , 2002, The Journal of Biological Chemistry.

[17]  K. Yeow,et al.  Expression of Sorsby's Fundus Dystrophy Mutations in Human Retinal Pigment Epithelial Cells Reduces Matrix Metalloproteinase Inhibition and May Promote Angiogenesis* , 2002, The Journal of Biological Chemistry.

[18]  R. Visse,et al.  Matrix Metalloproteinases Regulation and Dysregulation in the Failing Heart , 2002 .

[19]  Z. Galis,et al.  This Review Is Part of a Thematic Series on Matrix Metalloproteinases, Which Includes the following Articles: Matrix Metalloproteinase Inhibition after Myocardial Infarction: a New Approach to Prevent Heart Failure? Matrix Metalloproteinases in Vascular Remodeling and Atherogenesis: the Good, the Ba , 2022 .

[20]  K. Yeow,et al.  Sorsby's fundus dystrophy tissue inhibitor of metalloproteinases-3 (TIMP-3) mutants have unimpaired matrix metalloproteinase inhibitory activities, but affect cell adhesion to the extracellular matrix. , 2002, Matrix biology : journal of the International Society for Matrix Biology.

[21]  David B. Alexander,et al.  The Membrane-Anchored MMP Inhibitor RECK Is a Key Regulator of Extracellular Matrix Integrity and Angiogenesis , 2001, Cell.

[22]  C. Overall,et al.  Cellular Activation of MMP-2 (Gelatinase A) by MT2-MMP Occurs via a TIMP-2-independent Pathway* , 2001, The Journal of Biological Chemistry.

[23]  L. Matrisian,et al.  Matrix metalloproteinases: they're not just for matrix anymore! , 2001, Current opinion in cell biology.

[24]  S. Jain,et al.  Matrilysin cleavage of corneal collagen type XVIII NC1 domain and generation of a 28-kDa fragment. , 2001, Investigative ophthalmology & visual science.

[25]  H. Nar,et al.  Crystal structure of human macrophage elastase (MMP-12) in complex with a hydroxamic acid inhibitor. , 2001, Journal of molecular biology.

[26]  R. Huber,et al.  Substrate specificity determinants of human macrophage elastase (MMP-12) based on the 1.1 A crystal structure. , 2001, Journal of molecular biology.

[27]  Hiroshi Sato,et al.  Homophilic complex formation of MT1‐MMP facilitates proMMP‐2 activation on the cell surface and promotes tumor cell invasion , 2001, The EMBO journal.

[28]  G. Murphy,et al.  Specific collagenolysis by gelatinase A, MMP‐2, is determined by the hemopexin domain and not the fibronectin‐like domain , 2001, FEBS letters.

[29]  E. Creemers,et al.  Matrix Metalloproteinase Inhibition After Myocardial Infarction: A New Approach to Prevent Heart Failure? , 2001, Circulation research.

[30]  A. Roessner,et al.  Proteolysis of AA amyloid fibril proteins by matrix metalloproteinases-1, -2, and -3. , 2001, The American journal of pathology.

[31]  L. Matrisian,et al.  Osteopontin, a Novel Substrate for Matrix Metalloproteinase-3 (Stromelysin-1) and Matrix Metalloproteinase-7 (Matrilysin)* , 2001, The Journal of Biological Chemistry.

[32]  M. Llinás,et al.  Gelatin-binding Region of Human Matrix Metalloproteinase-2 , 2001, The Journal of Biological Chemistry.

[33]  MS Pepper,et al.  Extracellular Proteolysis and Angiogenesis , 2001, Thrombosis and Haemostasis.

[34]  Oonagh Dowling,et al.  Mutation of the matrix metalloproteinase 2 gene (MMP2) causes a multicentric osteolysis and arthritis syndrome , 2001, Nature Genetics.

[35]  C. Overall,et al.  Subcellular Distribution and Cytokine- and Chemokine-regulated Secretion of Leukolysin/MT6-MMP/MMP-25 in Neutrophils* , 2001, The Journal of Biological Chemistry.

[36]  A. Godzik,et al.  Characterization of matrix metalloproteinase-26, a novel metalloproteinase widely expressed in cancer cells of epithelial origin. , 2001, The Biochemical journal.

[37]  H. Lijnen.  Plasmin and Matrix Metalloproteinases in Vascular Remodeling , 2001, Thrombosis and Haemostasis.

[38]  H. Mori,et al.  Membrane-Type 1 Matrix Metalloproteinase Cleaves Cd44 and Promotes Cell Migration , 2001, The Journal of cell biology.

[39]  A. Strongin,et al.  Matrix-dependent Proteolysis of Surface Transglutaminase by Membrane-type Metalloproteinase Regulates Cancer Cell Adhesion and Locomotion* , 2001, The Journal of Biological Chemistry.

[40]  P. Libby,et al.  Tissue factor pathway inhibitor-2 is a novel inhibitor of matrix metalloproteinases with implications for atherosclerosis. , 2001, The Journal of clinical investigation.

[41]  M Kashiwagi,et al.  TIMP-3 Is a Potent Inhibitor of Aggrecanase 1 (ADAM-TS4) and Aggrecanase 2 (ADAM-TS5)* , 2001, The Journal of Biological Chemistry.

[42]  W. Parks,et al.  Epilysin, a Novel Human Matrix Metalloproteinase (MMP-28) Expressed in Testis and Keratinocytes and in Response to Injury* , 2001, The Journal of Biological Chemistry.

[43]  D. Moras,et al.  Crystal structure of the stromelysin-3 (MMP-11) catalytic domain complexed with a phosphinic inhibitor mimicking the transition-state. , 2001, Journal of molecular biology.

[44]  A. Strongin,et al.  MMP-28, a new human matrix metalloproteinase with an unusual cysteine-switch sequence is widely expressed in tumors. , 2001, Gene.

[45]  D. Chen,et al.  Cloning, expression, purification, and characterization of rat MMP-12. , 2001, Protein expression and purification.

[46]  Hiroyuki Arai,et al.  Matrix metalloproteinase (MMP) system in brain: identification and characterization of brain‐specific MMP highly expressed in cerebellum , 2001, The European journal of neuroscience.

[47]  G. Velasco,et al.  Catalytic activities of membrane‐type 6 matrix metalloproteinase (MMP25) , 2001, FEBS letters.

[48]  Y. Shimura,et al.  Differential roles of TIMP-4 and TIMP-2 in pro-MMP-2 activation by MT1-MMP. , 2001, Biochemical and biophysical research communications.

[49]  K. Appelt,et al.  Matrix Metalloproteinase Inhibitors for Cancer Therapy , 2000, Cancer Drug Discovery and Development.

[50]  D. Andrews,et al.  Reduced hydrolysis of amelogenin may result in X-linked amelogenesis imperfecta. , 2001, Matrix biology : journal of the International Society for Matrix Biology.

[51]  Z. Werb,et al.  How matrix metalloproteinases regulate cell behavior. , 2001, Annual review of cell and developmental biology.

[52]  H. Nagase.  Substrate Specificity of MMPs , 2001 .

[53]  I. Stamenkovic,et al.  Matrix metalloproteinase-7-mediated cleavage of Fas ligand protects tumor cells from chemotherapeutic drug cytotoxicity. , 2001, Cancer research.

[54]  M. Mareel,et al.  Release of an invasion promoter E-cadherin fragment by matrilysin and stromelysin-1. , 2001, Journal of cell science.

[55]  B. Sheu,et al.  A novel role of metalloproteinase in cancer-mediated immunosuppression. , 2001, Cancer research.

[56]  S. Zucker,et al.  Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment , 2000, Oncogene.

[57]  P. Declerck,et al.  Inactivation of Plasminogen Activator Inhibitor-1 by Specific Proteolysis with Stromelysin-1 (MMP-3)* , 2000, The Journal of Biological Chemistry.

[58]  J. Fox,et al.  ADAM 12-S cleaves IGFBP-3 and IGFBP-5 and is inhibited by TIMP-3. , 2000, Biochemical and biophysical research communications.

[59]  D. Pei,et al.  Cysteine Array Matrix Metalloproteinase (CA-MMP)/MMP-23 Is a Type II Transmembrane Matrix Metalloproteinase Regulated by a Single Cleavage for Both Secretion and Activation* , 2000, The Journal of Biological Chemistry.

[60]  H. Tschesche,et al.  Matrix Metalloproteinases Collagenase-2, Macrophage Elastase, Collagenase-3, and Membrane Type 1-Matrix Metalloproteinase Impair Clotting by Degradation of Fibrinogen and Factor XII* , 2000, The Journal of Biological Chemistry.

[61]  K. Brew,et al.  TIMP-3 Binds to Sulfated Glycosaminoglycans of the Extracellular Matrix* , 2000, The Journal of Biological Chemistry.

[62]  Shigeyoshi Itohara,et al.  Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis , 2000, Nature Cell Biology.

[63]  D. Dinakarpandian,et al.  Identification of the 183RWTNNFREY191Region as a Critical Segment of Matrix Metalloproteinase 1 for the Expression of Collagenolytic Activity* , 2000, The Journal of Biological Chemistry.

[64]  J. Goodship,et al.  A novel tissue inhibitor of metalloproteinases-3 mutation reveals a common molecular phenotype in Sorsby's fundus dystrophy. , 2000, The Journal of biological chemistry.

[65]  C. López-Otín,et al.  Matrilysin-2, a new matrix metalloproteinase expressed in human tumors and showing the minimal domain organization required for secretion, latency, and activity. , 2000, Cancer research.

[66]  P. Soloway,et al.  TIMP-2 Is Required for Efficient Activation of proMMP-2 in Vivo * , 2000, The Journal of Biological Chemistry.

[67]  C. Overall,et al.  Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3. , 2000, Science.

[68]  P. D. Di Cesare,et al.  Matrix metalloproteinases 19 and 20 cleave aggrecan and cartilage oligomeric matrix protein (COMP) , 2000, FEBS letters.

[69]  Jian Ni,et al.  Identification and Characterization of Human Endometase (Matrix Metalloproteinase-26) from Endometrial Tumor* , 2000, The Journal of Biological Chemistry.

[70]  C. López-Otín,et al.  Biochemical Characterization of the Catalytic Domain of Human Matrix Metalloproteinase 19 , 2000, The Journal of Biological Chemistry.

[71]  P. Slocombe,et al.  The in vitro activity of ADAM‐10 is inhibited by TIMP‐1 and TIMP‐3 , 2000, FEBS letters.

[72]  X. Puente,et al.  Membrane Type 4 Matrix Metalloproteinase (MMP17) Has Tumor Necrosis Factor-α Convertase Activity but Does Not Activate Pro-MMP2* , 2000, The Journal of Biological Chemistry.

[73]  K. Brew,et al.  Tissue inhibitors of metalloproteinases: evolution, structure and function. , 2000, Biochimica et biophysica acta.

[74]  A. Leontovich,et al.  A novel hydra matrix metalloproteinase (HMMP) functions in extracellular matrix degradation, morphogenesis and the maintenance of differentiated cells in the foot process. , 2000, Development.

[75]  A. Ferrando,et al.  Human MT6-matrix metalloproteinase: identification, progelatinase A activation, and expression in brain tumors. , 2000, Cancer research.

[76]  G. Giannelli,et al.  Role of Cell Surface Metalloprotease Mt1-Mmp in Epithelial Cell Migration over Laminin-5 , 2000, The Journal of cell biology.

[77]  H. J. Kim,et al.  Analysis of tissue inhibitor of metalloproteinases-2 effect on pro-matrix metalloproteinase-2 activation by membrane-type 1 matrix metalloproteinase using baculovirus/insect-cell expression system. , 2000, The Biochemical journal.

[78]  I. Stamenkovic,et al.  Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. , 2000, Genes & development.

[79]  J. Mott,et al.  Post-translational Proteolytic Processing of Procollagen C-terminal Proteinase Enhancer Releases a Metalloproteinase Inhibitor* , 2000, The Journal of Biological Chemistry.

[80]  J. Woessner,et al.  Matrix metalloproteinases and TIMPs , 2000 .

[81]  B. Fingleton,et al.  The metalloproteinase matrilysin proteolytically generates active soluble Fas ligand and potentiates epithelial cell apoptosis , 1999, Current Biology.

[82]  Jianxun Lei,et al.  Expression, purification and charaterization of recombinant mouse MT5‐MMP protein products , 1999, FEBS letters.

[83]  G. Murphy,et al.  Matrix Metalloproteinase Homologues from Arabidopsis thaliana , 1999, The Journal of Biological Chemistry.

[84]  D. Pei.  Leukolysin/MMP25/MT6-MMP: a novel matrix metalloproteinase specifically expressed in the leukocyte lineage , 1999, Cell Research.

[85]  R. D. Dyer,et al.  Catalytic Activities and Substrate Specificity of the Human Membrane Type 4 Matrix Metalloproteinase Catalytic Domain* , 1999, The Journal of Biological Chemistry.

[86]  M. Radomski,et al.  Vascular matrix metalloproteinase-2 cleaves big endothelin-1 yielding a novel vasoconstrictor. , 1999, Circulation research.

[87]  J. Folkman,et al.  Regulation of Angiostatin Production by Matrix Metalloproteinase-2 in a Model of Concomitant Resistance* , 1999, The Journal of Biological Chemistry.

[88]  L. Matrisian,et al.  Regulation of intestinal alpha-defensin activation by the metalloproteinase matrilysin in innate host defense. , 1999, Science.

[89]  P. DenBesten,et al.  Activation of recombinant bovine matrix metalloproteinase-20 and its hydrolysis of two amelogenin oligopeptides. , 1999, European journal of oral sciences.

[90]  J. Ward,et al.  MT1-MMP-Deficient Mice Develop Dwarfism, Osteopenia, Arthritis, and Connective Tissue Disease due to Inadequate Collagen Turnover , 1999, Cell.

[91]  D. Pei.  CA‐MMP: a matrix metalloproteinase with a novel cysteine array, but without the classic cysteine switch , 1999, FEBS letters.

[92]  J. Caillaud,et al.  Adenovirus-mediated overexpression of tissue inhibitor of metalloproteinase-1 reduces atherosclerotic lesions in apolipoprotein E-deficient mice. , 1999, Circulation.

[93]  G. Schneider,et al.  Structure of human pro-matrix metalloproteinase-2: activation mechanism revealed. , 1999, Science.

[94]  Y. Okada,et al.  Characterization of a truncated recombinant form of human membrane type 3 matrix metalloproteinase. , 1999, European journal of biochemistry.

[95]  C. López-Otín,et al.  Identification and characterization of human MT5-MMP, a new membrane-bound activator of progelatinase a overexpressed in brain tumors. , 1999, Cancer research.

[96]  Temple F. Smith,et al.  The WD repeat: a common architecture for diverse functions. , 1999, Trends in biochemical sciences.

[97]  H. Erdjument-Bromage,et al.  Tissue inhibitor of metalloproteinase-2 stimulates mesenchymal growth and regulates epithelial branching during morphogenesis of the rat metanephros. , 1999, The Journal of clinical investigation.

[98]  U. Thorgeirsson,et al.  Tissue inhibitor of metalloproteinases-1 (TIMP-1) binds to the cell surface and translocates to the nucleus of human MCF-7 breast carcinoma cells. , 1999, Biochemical and biophysical research communications.

[99]  W. Bode,et al.  Structural properties of matrix metalloproteinases , 1999, Cellular and Molecular Life Sciences CMLS.

[100]  D. Pei.  Identification and Characterization of the Fifth Membrane-type Matrix Metalloproteinase MT5-MMP* , 1999, The Journal of Biological Chemistry.

[101]  C. López-Otín,et al.  Cloning and Characterization of Human MMP-23, a New Matrix Metalloproteinase Predominantly Expressed in Reproductive Tissues and Lacking Conserved Domains in Other Family Members* , 1999, The Journal of Biological Chemistry.

[102]  H. Kolkenbrock,et al.  Biochemical Characterization of the Catalytic Domain of Membrane-Type 4 Matrix Metalloproteinase , 1999, Biological chemistry.

[103]  M. Cilli,et al.  TIMP‐2, Over‐expression reduces invasion and angiogenesis and protects B16F10 melanoma cells from apoptosis. Int. J. Cancer 75, 246–253 (1998) , 1999, International journal of cancer.

[104]  R. Pierce,et al.  Matrix metalloproteinases generate angiostatin: effects on neovascularization. , 1998, Journal of immunology.

[105]  Y Ikawa,et al.  Regulation of matrix metalloproteinase-9 and inhibition of tumor invasion by the membrane-anchored glycoprotein RECK. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[106]  P. Libby,et al.  Generation of Biologically Active IL-1β by Matrix Metalloproteinases: A Novel Caspase-1-Independent Pathway of IL-1β Processing , 1998, The Journal of Immunology.

[107]  É. Allaire,et al.  Local overexpression of TIMP-1 prevents aortic aneurysm degeneration and rupture in a rat model. , 1998, The Journal of clinical investigation.

[108]  P. Slocombe,et al.  TNF‐α converting enzyme (TACE) is inhibited by TIMP‐3 , 1998 .

[109]  J. Calvete,et al.  Crystal structure of the complex formed by the membrane type 1‐matrix metalloproteinase with the tissue inhibitor of metalloproteinases‐2, the soluble progelatinase A receptor , 1998, The EMBO journal.

[110]  M. Stetler-Stevenson,et al.  Tissue inhibitor of metalloproteinase (TIMP)-1 induces differentiation and an antiapoptotic phenotype in germinal center B cells. , 1998, Blood.

[111]  M J Bissell,et al.  Expression of autoactivated stromelysin-1 in mammary glands of transgenic mice leads to a reactive stroma during early development. , 1998, The American journal of pathology.

[112]  N. Ohba,et al.  A novel splice site mutation in the tissue inhibitor of the metalloproteinases-3 gene in Sorsby’s fundus dystrophy with unusual clinical features , 1998, Human Genetics.

[113]  M. Kurkinen,et al.  Cloning and Characterization of a Novel Matrix Metalloproteinase (MMP), CMMP, from Chicken Embryo Fibroblasts , 1998, The Journal of Biological Chemistry.

[114]  D. Collen,et al.  Proteolytic cleavage of urokinase-type plasminogen activator by stromelysin-1 (MMP-3). , 1998, Biochemistry.

[115]  Y. Okada,et al.  Transformation of epithelial Madin-Darby canine kidney cells with p60(v-src) induces expression of membrane-type 1 matrix metalloproteinase and invasiveness. , 1998, Cancer research.

[116]  T. Hoshino,et al.  Cell cycle-associated accumulation of tissue inhibitor of metalloproteinases-1 (TIMP-1) in the nuclei of human gingival fibroblasts. , 1998, Journal of cell science.

[117]  E. Ohuchi,et al.  Activation of the precursor of human stromelysin 2 and its interactions with other matrix metalloproteinases. , 1998, European journal of biochemistry.

[118]  H. Lijnen,et al.  Generation of an angiostatin-like fragment from plasminogen by stromelysin-1 (MMP-3). , 1998, Biochemistry.

[119]  K. Brew,et al.  Expression of Human Pro-Matrix Metalloproteinase 3 that Lacks the N-terminal 34 Residues in Escherichia coli: Autoactivation and Interaction with Tissue Inhibitor of Metalloproteinase 1 (TIMP-1) , 1998, Biological chemistry.

[120]  Gillian Murphy,et al.  The TIMP2 Membrane Type 1 Metalloproteinase “Receptor” Regulates the Concentration and Efficient Activation of Progelatinase A , 1998, The Journal of Biological Chemistry.

[121]  J. Woessner,et al.  The Matrix Metalloproteinase Family , 1998 .

[122]  U. Felbor,et al.  [Sorsby's fundus dystrophy. A genetically homogeneous disease]. , 1998, Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft.

[123]  Z. Werb,et al.  Matrix Metalloproteinase Stromelysin-1 Triggers a Cascade of Molecular Alterations That Leads to Stable Epithelial-to-Mesenchymal Conversion and a Premalignant Phenotype in Mammary Epithelial Cells , 1997, The Journal of cell biology.

[124]  R. Timpl,et al.  Membrane-type matrix metalloproteinases 1 and 2 exhibit broad-spectrum proteolytic capacities comparable to many matrix metalloproteinases. , 1997, European journal of biochemistry.

[125]  R. Fridman,et al.  Kinetic Analysis of the Binding of Human Matrix Metalloproteinase-2 and -9 to Tissue Inhibitor of Metalloproteinase (TIMP)-1 and TIMP-2* , 1997, The Journal of Biological Chemistry.

[126]  B. C. Patterson,et al.  Angiostatin-converting Enzyme Activities of Human Matrilysin (MMP-7) and Gelatinase B/Type IV Collagenase (MMP-9)* , 1997, The Journal of Biological Chemistry.

[127]  M. Barbacid,et al.  Identification of Insulin-like Growth Factor-binding Protein-1 as a Potential Physiological Substrate for Human Stromelysin-3* , 1997, The Journal of Biological Chemistry.

[128]  D. Gomez,et al.  Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. , 1997, European journal of cell biology.

[129]  S. Itohara,et al.  Unaltered Secretion of β-Amyloid Precursor Protein in Gelatinase A (Matrix Metalloproteinase 2)-deficient Mice* , 1997, The Journal of Biological Chemistry.

[130]  R. Huber,et al.  Mechanism of inhibition of the human matrix metalloproteinase stromelysin-1 by TIMP-1 , 1997, Nature.

[131]  L. Holliday,et al.  Initiation of Osteoclast Bone Resorption by Interstitial Collagenase* , 1997, The Journal of Biological Chemistry.

[132]  G. Giannelli,et al.  Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5. , 1997, Science.

[133]  D. Taub,et al.  A dominant negative mutant of jun blocking 12‐O‐tetradecanoylphorbol‐13‐acetate–induced invasion in mouse keratinocytes , 1997, Molecular carcinogenesis.

[134]  William C. Parks,et al.  The Activity of Collagenase-1 Is Required for Keratinocyte Migration on a Type I Collagen Matrix , 1997, The Journal of cell biology.

[135]  U. Krawinkel,et al.  The matrix metalloproteinase RASI-1 is expressed in synovial blood vessels of a rheumatoid arthritis patient. , 1997, Immunology letters.

[136]  H. V. Van Wart,et al.  Hydrolysis of a Broad Spectrum of Extracellular Matrix Proteins by Human Macrophage Elastase* , 1997, The Journal of Biological Chemistry.

[137]  A. Pollock,et al.  Gelatinase A is a glomerular mesangial cell growth and differentiation factor. , 1997, Kidney international.

[138]  M. Radomski,et al.  Release of gelatinase A during platelet activation mediates aggregation , 1997, Nature.

[139]  R. Timpl,et al.  Limited Cleavage of Extracellular Matrix Protein BM-40 by Matrix Metalloproteinases Increases Its Affinity for Collagens* , 1997, The Journal of Biological Chemistry.

[140]  C. López-Otín,et al.  The Role of the C-terminal Domain of Human Collagenase-3 (MMP-13) in the Activation of Procollagenase-3, Substrate Specificity, and Tissue Inhibitor of Metalloproteinase Interaction* , 1997, The Journal of Biological Chemistry.

[141]  I. Fidler,et al.  Macrophage-Derived Metalloelastase Is Responsible for the Generation of Angiostatin in Lewis Lung Carcinoma , 1997, Cell.

[142]  Y. Okada,et al.  Degradation of decorin by matrix metalloproteinases: identification of the cleavage sites, kinetic analyses and transforming growth factor-beta1 release. , 1997, The Biochemical journal.

[143]  H. Nagase.  Activation mechanisms of matrix metalloproteinases. , 1997, Biological chemistry.

[144]  G. Butler,et al.  Membrane-type-2 matrix metalloproteinase can initiate the processing of progelatinase A and is regulated by the tissue inhibitors of metalloproteinases. , 1997, European journal of biochemistry.

[145]  X. Puente,et al.  Identification and Characterization of a Novel Human Matrix Metalloproteinase with Unique Structural Characteristics, Chromosomal Location, and Tissue Distribution* , 1997, The Journal of Biological Chemistry.

[146]  Y. Okada,et al.  Membrane Type 1 Matrix Metalloproteinase Digests Interstitial Collagens and Other Extracellular Matrix Macromolecules* , 1997, The Journal of Biological Chemistry.

[147]  N. Guex,et al.  SWISS‐MODEL and the Swiss‐Pdb Viewer: An environment for comparative protein modeling , 1997, Electrophoresis.

[148]  E. Furth,et al.  A program of cell death and extracellular matrix degradation is activated in the amnion before the onset of labor. , 1996, The Journal of clinical investigation.

[149]  Y. Itoh,et al.  Degradation of cross-linked fibrin by matrix metalloproteinase 3 (stromelysin 1): hydrolysis of the gamma Gly 404-Ala 405 peptide bond. , 1996, Biochemistry.

[150]  Q. A. Sang,et al.  Identification and characterization of a novel collagenase in Xenopus laevis: possible roles during frog development. , 1996, Molecular biology of the cell.

[151]  G. Butler,et al.  The Soluble Catalytic Domain of Membrane Type 1 Matrix Metalloproteinase Cleaves the Propeptide of Progelatinase A and Initiates Autoproteolytic Activation , 1996, The Journal of Biological Chemistry.

[152]  C. López-Otín,et al.  Cellular Mechanisms for Human Procollagenase-3 (MMP-13) Activation , 1996, The Journal of Biological Chemistry.

[153]  Y. Sasaguri,et al.  Degradation of Interleukin 1β by Matrix Metalloproteinases* , 1996, The Journal of Biological Chemistry.

[154]  T. Ley,et al.  Metalloelastase is required for macrophage-mediated proteolysis and matrix invasion in mice. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[155]  John M. Whitelock,et al.  The Degradation of Human Endothelial Cell-derived Perlecan and Release of Bound Basic Fibroblast Growth Factor by Stromelysin, Collagenase, Plasmin, and Heparanases (*) , 1996, The Journal of Biological Chemistry.

[156]  Qi-Zhuang Ye,et al.  The Structural Basis for the Elastolytic Activity of the 92-kDa and 72-kDa Gelatinases , 1996, The Journal of Biological Chemistry.

[157]  G. Fields,et al.  Human matrix metalloproteinase specificity studies using collagen sequence-based synthetic peptides. , 1996, Biopolymers.

[158]  William Arbuthnot Sir Lane,et al.  Glial hyaluronate-binding protein: a product of metalloproteinase digestion of versican? , 1995, The Biochemical journal.

[159]  Jack P. Witty,et al.  Matrix metalloproteinases are expressed during ductal and alveolar mammary morphogenesis, and misregulation of stromelysin-1 in transgenic mice induces unscheduled alveolar development. , 1995, Molecular biology of the cell.

[160]  J. Springer,et al.  Stromelysin‐1: Three‐dimensional structure of the inhibited catalytic domain and of the C‐truncated proenzyme , 1995, Protein science : a publication of the Protein Society.

[161]  Hiroshi Sato,et al.  Identification of the Second Membrane-type Matrix Metalloproteinase (MT-MMP-2) Gene from a Human Placenta cDNA Library , 1995, The Journal of Biological Chemistry.

[162]  H. Yajima,et al.  Release of biological activities from quiescent fibronectin by a conformational change and limited proteolysis by matrix metalloproteinases. , 1995, Biochemistry.

[163]  K. Suzuki,et al.  Characterization of insulin-like growth factor-binding protein 5-degrading proteases produced throughout murine osteoblast differentiation. , 1995, Endocrinology.

[164]  P. Barker,et al.  Binding of gelatinases A and B to type-I collagen and other matrix components. , 1995, The Biochemical journal.

[165]  B. Hazleman,et al.  Structure of full-length porcine synovial collagenase reveals a C-terminal domain containing a calcium-linked, four-bladed beta-propeller. , 1995, Structure.

[166]  Y. Itoh,et al.  Steps involved in activation of the complex of pro-matrix metalloproteinase 2 (progelatinase A) and tissue inhibitor of metalloproteinases (TIMP)-2 by 4-aminophenylmercuric acetate. , 1995, The Biochemical journal.

[167]  Stephen J. Weiss,et al.  Furin-dependent intracellular activation of the human stromelysin-3 zymogen , 1995, Nature.

[168]  James P. Quigley,et al.  Matrix Metalloproteinase-2 Is an Interstitial Collagenase , 1995, The Journal of Biological Chemistry.

[169]  A. Strongin,et al.  Mechanism Of Cell Surface Activation Of 72-kDa Type IV Collagenase , 1995, The Journal of Biological Chemistry.

[170]  Z. Werb,et al.  Suppression of ICE and apoptosis in mammary epithelial cells by extracellular matrix , 1995, Science.

[171]  J. Quigley,et al.  Matrix metalloproteinase-2 is an interstitial collagenase. Inhibitor-free enzyme catalyzes the cleavage of collagen fibrils and soluble native type I collagen generating the specific 3/4- and 1/4-length fragments. , 1995, The Journal of biological chemistry.

[172]  R. Pruett,et al.  Mutations in the tissue inhibitor of metalloproteinases-3 (TIMP3) in patients with Sorsby's fundus dystrophy , 1994, Nature Genetics.

[173]  L. Liotta,et al.  Galectin-3 is a novel substrate for human matrix metalloproteinases-2 and -9. , 1994, Biochemistry.

[174]  S. Weiss,et al.  Hydrolytic inactivation of a breast carcinoma cell-derived serpin by human stromelysin-3. , 1994, The Journal of biological chemistry.

[175]  K. Suzuki,et al.  Matrix metalloproteinases degrade insulin-like growth factor-binding protein-3 in dermal fibroblast cultures. , 1994, The Journal of biological chemistry.

[176]  R. Williamson,et al.  Solution structure of the active domain of tissue inhibitor of metalloproteinases-2. A new member of the OB fold protein family. , 1994, Biochemistry.

[177]  A. Shinagawa,et al.  Cell growth-promoting activity of tissue inhibitor of metalloproteinases-2 (TIMP-2). , 1994, Journal of cell science.

[178]  Z. Werb,et al.  Targeted expression of stromelysin-1 in mammary gland provides evidence for a role of proteinases in branching morphogenesis and the requirement for an intact basement membrane for tissue-specific gene expression [published erratum appears in J Cell Biol 1996 Feb;132(4):following 752] , 1994, The Journal of cell biology.

[179]  M. Cockett,et al.  Assessment of the role of the fibronectin-like domain of gelatinase A by analysis of a deletion mutant. , 1994, The Journal of biological chemistry.

[180]  T. Ley,et al.  Cloning and characterization of a unique elastolytic metalloproteinase produced by human alveolar macrophages. , 1993, The Journal of biological chemistry.

[181]  W. Stetler-Stevenson,et al.  Tissue inhibitor of metalloproteinases‐2 inhibits bFGF‐induced human microvascular endothelial cell proliferation , 1993, Journal of cellular physiology.

[182]  H. Nagase,et al.  Disruption of the cysteine-75 and zinc ion coordination is not sufficient to activate the precursor of human matrix metalloproteinase 3 (stromelysin 1). , 1993, Biochemistry.

[183]  W. Bode,et al.  Astacins, serralysins, snake venom and matrix metalloproteinases exhibit identical zinc‐binding environments (HEXXHXXGXXH and Met‐turn) and topologies and should be grouped into a common family, the ‘metzincins’ , 1993, FEBS letters.

[184]  P. Chambon,et al.  The 28-kDa N-terminal domain of mouse stromelysin-3 has the general properties of a weak metalloproteinase. , 1993, The Journal of biological chemistry.

[185]  Miki Hasegawa,et al.  A metalloproteinase inhibitor domain in Alzheimer amyloid protein precursor , 1993, Nature.

[186]  K. Iwata,et al.  Growth‐promoting activity of tissue inhibitor of metalloproteinases‐1 (TIMP‐1) for a wide range of cells A possible new growth factor in serum , 1992, FEBS letters.

[187]  W. Stetler-Stevenson,et al.  Tissue inhibitor of metalloproteinase‐2 (TIMP‐2) has erythroid‐potentiating activity , 1992, FEBS letters.

[188]  R. Williamson,et al.  The N-terminal domain of tissue inhibitor of metalloproteinases retains metalloproteinase inhibitory activity. , 1991, Biochemistry.

[189]  K. Suzuki,et al.  Mechanisms of activation of tissue procollagenase by matrix metalloproteinase 3 (stromelysin). , 1990, Biochemistry.

[190]  T. Lepage,et al.  Early expression of a collagenase‐like hatching enzyme gene in the sea urchin embryo. , 1990, The EMBO journal.

[191]  H. Birkedal‐Hansen,et al.  The cysteine switch: a principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[192]  K. Suzuki,et al.  Stepwise activation mechanisms of the precursor of matrix metalloproteinase 3 (stromelysin) by proteinases and (4-aminophenyl)mercuric acetate. , 1990, Biochemistry.

[193]  H. Morris,et al.  Disulphide bond assignment in human tissue inhibitor of metalloproteinases (TIMP). , 1990, The Biochemical journal.

[194]  Y. Okada,et al.  The precursor of a metalloendopeptidase from human rheumatoid synovial fibroblasts. Purification and mechanisms of activation by endopeptidases and 4-aminophenylmercuric acetate. , 1988, The Biochemical journal.

[195]  T. Cawston,et al.  Preferential binding of collagenase to α2‐macroglobulin in the presence of the tissue inhibitor of metalloproteinases , 1986, FEBS letters.

[196]  E. Brown,et al.  Molecular characterization and expression of the gene encoding human erythroid-potentiating activity , 1985, Nature.

[197]  K. Hagino-Yamagishi,et al.  [Oncogene]. , 2019, Gan to kagaku ryoho. Cancer & chemotherapy.

[198]  A. Barrett.  [54] α2-Macroglobulin , 1981 .